IBEX Wealth Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-903
Closed -$68K 354
2021
Q3
$68K Buy
+903
New +$68.8K 0.01% 251
2019
Q3
Sell
-1,157
Closed -$61K 295
2019
Q2
$61K Buy
+1,157
New +$60K 0.02% 199
2017
Q1
Sell
-1,364
Closed -$54K 282
2016
Q4
$54K Buy
+1,364
New +$55.1K 0.03% 171

Other funds holding PBE

IBEX Wealth Advisors's PBE Position: Q4 2021 in Review

IBEX Wealth Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2021, closing a stake of 903 shares — an estimated $68K sold.

IBEX Wealth Advisors first reported a position in PBE in Q4 2016 and held it in 3 quarters. The position peaked at $68K in Q3 2021. 101 funds tracked by Wall St. Rank hold PBE as of Q4 2021.

  • IBEX Wealth Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2021 after selling out during the quarter.
  • IBEX Wealth Advisors sold 903 Invesco Biotechnology & Genome ETF shares in Q4 2021, an estimated $68K.
  • IBEX Wealth Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2016 and held it in 3 quarters.
  • IBEX Wealth Advisors's Invesco Biotechnology & Genome ETF position peaked at $68K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2021.

Based on IBEX Wealth Advisors's 13F filing for Q4 2021, filed 22 Feb 2022.